financetom
Business
financetom
/
Business
/
Summit Therapeutics Expands Phase III Ivonescimab Program Into Colorectal Cancer
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Summit Therapeutics Expands Phase III Ivonescimab Program Into Colorectal Cancer
Oct 17, 2025 5:43 AM

08:29 AM EDT, 10/17/2025 (MT Newswires) -- Summit Therapeutics ( SMMT ) said Friday it is initiating a phase III trial to evaluate bispecific antibody ivonescimab as a first line therapy in patients with unresectable metastatic colorectal cancer.

The biopharmaceutical company said the trial represents a first global study of ivonescimab beyond non-small cell lung cancer. The phase III trial will evaluate the antibody plus chemotherapy compared with bevacizumab plus chemotherapy.

Summit said it plans to enroll approximately 600 patients in the trial and that the study's primary endpoint is progression-free survival.

Summit Therapeutics ( SMMT ) shares were down 1.7% in recent premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved